Medpace Holdings, Inc. $MEDP Shares Purchased by HighTower Advisors LLC

HighTower Advisors LLC increased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 37.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,453 shares of the company’s stock after purchasing an additional 1,476 shares during the period. HighTower Advisors LLC’s holdings in Medpace were worth $3,063,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. AQR Capital Management LLC raised its position in Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after buying an additional 404,226 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after buying an additional 211,411 shares during the last quarter. Wasatch Advisors LP raised its position in Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after buying an additional 116,354 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in Medpace by 24,930.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company’s stock worth $56,936,000 after buying an additional 100,968 shares during the last quarter. Finally, Invesco Ltd. raised its position in Medpace by 18.9% during the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after buying an additional 85,517 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Bronstein, Gewirtz & Grossman, Faruqi & Faruqi, The Gross Law Firm, Rosen, Schall, Pomerantz, and others, issued updates this week about a pending class-action lawsuit against Medpace and reminded shareholders of upcoming lead-plaintiff deadlines, keeping legal risk in focus for the stock. Article Title
• Neutral Sentiment: The latest notices do not add new operational or financial guidance from Medpace; they mainly reiterate the same securities-fraud allegations and court deadline, so the immediate market impact is likely driven more by headline risk than by fundamentals. Article Title
• Neutral Sentiment: Short-interest data released alongside the legal headlines showed no meaningful borrowable shares reported, suggesting the move in MEDP is being driven by news flow rather than a clear short-selling signal.

Medpace Stock Down 0.2%

Shares of MEDP opened at $447.11 on Friday. The company has a 50-day simple moving average of $457.47 and a 200-day simple moving average of $513.97. The company has a market capitalization of $12.77 billion, a PE ratio of 28.10, a P/E/G ratio of 2.27 and a beta of 1.19. Medpace Holdings, Inc. has a 52-week low of $291.28 and a 52-week high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business’s revenue was up 26.5% compared to the same quarter last year. During the same quarter last year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts anticipate that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Wall Street Analysts Forecast Growth

MEDP has been the subject of a number of analyst reports. BMO Capital Markets cut their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th. Truist Financial cut their price objective on shares of Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research report on Wednesday, February 11th. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and cut their price objective for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Mizuho set a $582.00 price objective on shares of Medpace in a research report on Wednesday, February 11th. Finally, Weiss Ratings downgraded shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Medpace presently has an average rating of “Hold” and an average price target of $467.08.

Insider Activity

In other news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president owned 15,000 shares in the company, valued at $6,829,500. This trade represents a 67.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 20.50% of the stock is owned by corporate insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.